|
| | Publication Year | Title | Author(s) |
| 61 | 1-Oct-2021 | First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. | Reck, M; Ciuleanu, T-E; Cobo, M; Schenker, M; Zurawski, B; Menezes, J; Richardet, E; Bennouna, J; Felip, E; Juan-Vidal, O; Alexandru, A; Sakai, H; Lingua, A; Reyes, F; Souquet, P-J; De Marchi, P; Martin, C; Pérol, M; Scherpereel, A; Lu, S; Paz-Ares, L; Carbone, D P; Memaj, A; Marimuthu, S; Zhang, X; Tran, P; John, Thomas |
| 62 | Oct-2021 | Colorimetric histology using plasmonically active microscope slides. | Balaur, Eugeniu; O' Toole, Sandra; Spurling, Alex J; Mann, G Bruce; Yeo, Belinda ; Harvey, Kate; Sadatnajafi, Catherine; Hanssen, Eric; Orian, Jacqueline; Nugent, Keith A; Parker, Belinda S; Abbey, Brian |
| 63 | Oct-2021 | A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. | Gan, Hui K ; Millward, Michael; Jalving, Mathilde; Garrido-Laguna, Ignacio; Lickliter, Jason D; Schellens, Jan H M; Lolkema, Martijn P; Van Herpen, Carla L M; Hug, Bruce; Tang, Lihua; O'Connor-Semmes, Robin; Gagnon, Robert; Ellis, Catherine; Ganji, Gopinath; Matheny, Christopher; Drilon, Alexander |
| 64 | 15-Sep-2021 | Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. | Nesic, Ksenija; Kondrashova, Olga; Hurley, Rachel M; McGehee, Cordelia D; Vandenberg, Cassandra J; Ho, Gwo-Yaw; Lieschke, Elizabeth; Dall, Genevieve; Bound, Nirashaa; Shield-Artin, Kristy; Radke, Marc; Musafer, Ashan; Chai, Zi Qing; Ghamsari, Mohammad Reza Eftekhariyan; Harrell, Maria I; Kee, Damien ; Olesen, Inger; McNally, Orla; Traficante, Nadia; Australian Ovarian Cancer Study, null; DeFazio, Anna; Bowtell, David D L; Swisher, Elizabeth M; Weroha, S John; Nones, Katia; Waddell, Nicola; Kaufmann, Scott H; Dobrovic, Alexander ; Wakefield, Matthew J; Scott, Clare L |
| 65 | 3-Aug-2021 | Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. | Gan, Hui K ; Parakh, Sagun ; Lassman, Andrew B; Seow, Aidan; Lau, Eddie ; Lee, Sze Ting ; Ameratunga, Malaka; Perchyonok, Yuliya ; Cao, Diana; Burvenich, Ingrid J G; O'Keefe, Graeme J; Rigopoulos, Angela; Gomez, Erica; Maag, David; Scott, Andrew M |
| 66 | Aug-2021 | The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020? | Harel, Nadav; Cheema, Steven ; Williams, David S ; Ireland-Jenkin, Kerryn ; Fancourt, Tineke ; Dodson, Andrew; Yeo, Belinda |
| 67 | 1-Jul-2021 | Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non-Small Cell Lung Cancer: Comparison of Assessment Methods. | Ayati, Narjess ; Lee, Sze Ting ; Zakavi, S Rasoul; Cheng, Melissa; Lau, W F Eddie; Parakh, Sagun ; Pathmaraj, Kunthi ; Scott, Andrew M |
| 68 | Jul-2021 | Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. | Kyriakos, Nikolaos; Papaefthymiou, Apostolis; Giakoumis, Marios; Iatropoulos, George F ; Mantzaris, Gerasimos; Liatsos, Christos |
| 69 | 15-Jun-2021 | Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M ; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 70 | 9-Jun-2021 | PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. | Parakh, Sagun ; Musafer, Ashan; Paessler, Sabrina; Witkowski, Tom ; Suen, Connie S N Li Wai; Tutuka, Candani S A; Carlino, Matteo S; Menzies, Alexander M; Scolyer, Richard A; Cebon, Jonathan S ; Dobrovic, Alexander ; Long, Georgina V; Klein, Oliver ; Behren, Andreas |
| 71 | 1-Jun-2021 | Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. | Yin, Jun; Cohen, Romain; Jin, Zhaohui; Liu, Heshan; Pederson, Levi; Adams, Richard; Grothey, Axel; Maughan, Timothy S; Venook, Alan; Van Cutsem, Eric; Punt, Cornelis; Koopman, Miriam; Falcone, Alfredo; Tebbutt, Niall C ; Seymour, Matthew T; Bokemeyer, Carsten; Rubio, Eduardo Diaz; Kaplan, Richard; Heinemann, Volker; Chibaudel, Benoist; Yoshino, Takayuki; Zalcberg, John; Andre, Thierry; De Gramont, Aimery; Shi, Qian; Lenz, Heinz-Josef |
| 72 | 28-May-2021 | A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Jenkins, Laura J; Poh, Ashleigh R; Walkiewicz, Marzena; Leong, Trishe; Mariadason, John M ; Cebon, Jonathan S ; Balachander, Srividya B; Cidado, Justin R; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 73 | May-2021 | Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years. | Loh, Zoe ; Salvaris, Ross; Chong, Geoffrey ; Churilov, Leonid ; Manos, Kate ; Barraclough, Allison ; Hawkes, Eliza A |
| 74 | May-2021 | Prevalence of hypoxia and correlation with glycolytic metabolism and angiogenic biomarkers in metastatic colorectal carcinoma. | Lee, Sze Ting ; Muralidharan, Vijayaragavan ; Tebbutt, Niall C ; Wong, P; Fang, C; Liu, Z; Gan, Hui K ; Sachinidis, J; Pathmaraj, Kunthi ; Christophi, Christopher ; Scott, Andrew M |
| 75 | 29-Apr-2021 | Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Carlino, Matteo S; Underhill, Craig; Palmer, Jodie ; Power, Daniel; Cebon, Jonathan S ; Behren, Andreas |
| 76 | 12-Apr-2021 | Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. | Klein, Oliver ; Senko, Clare ; Carlino, Matteo S; Markman, Ben; Jackett, Louise A ; Gao, Bo; Lum, Caroline; Kee, Damien ; Behren, Andreas; Palmer, Jodie ; Cebon, Jonathan S |
| 17 | 9-Apr-2021 | Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. | Da Gama Duarte, Jessica; Woods, Katherine; Quigley, Luke T; Deceneux, Cyril; Tutuka, Candani; Witkowski, Tom ; Ostrouska, Simone; Hudson, Chris; Tsao, Simon Chang-Hao; Pasam, Anupama; Dobrovic, Alexander ; Blackburn, Jonathan M; Cebon, Jonathan S ; Behren, Andreas |
| 18 | Apr-2021 | The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. | Arulananda, Surein; Lee, Erinna F; Fairlie, Walter Douglas ; John, Thomas |
| 19 | 17-Mar-2021 | Evaluation of 18F-FMISO PET and 18F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy. | Lee, Sze Ting ; Tebbutt, Niall C ; Gan, Hui K ; Liu, Zhanqi; Sachinidis, John; Pathmaraj, Kunthi ; Scott, Andrew M |
| 20 | Mar-2021 | Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. | Gleeson, Mary; Counsell, Nicholas; Cunningham, David; Lawrie, Anthony; Clifton-Hadley, Laura; Hawkes, Eliza A ; McMillan, Andrew; Ardeshna, Kirit M; Burton, Cathy; Chadwick, Nick; Gambell, Joanna; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Radford, John; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter; Linch, David |
